Advertisement

Substance Use and Adherence to Antiretroviral Therapy: What Is Known and What Is Unknown

  • M. Eugenia Socias
  • M-J Milloy
HIV/AIDs (C Yoon, Section Editor)
  • 48 Downloads
Part of the following topical collections:
  1. Topical Collection on HIV/AIDS

Abstract

Purpose of Review

People who use drugs face multiple challenges to achieve optimal HIV treatment outcomes. This review discusses the current knowledge in substance use and antiretroviral therapy adherence, highlighting recent findings and potential interventions.

Recent Findings

Studies continue to demonstrate the negative impacts of substance use and related disorders on antiretroviral therapy adherence, with the exception of cannabis. Evidence-based addiction treatment, in particular, opioid agonist therapy, appears to improve adherence levels. Most individual-level adherence specific interventions did not provide sustained effects, and no studies evaluating structural-level interventions were found.

Summary

Findings suggest the urgent need to scale-up opioid agonist therapy, as well as to simultaneously address multiple structural barriers to care to optimize HIV treatment outcomes among people who use drugs.

Keywords

Adherence Antiretroviral therapy People who use drugs People who inject drugs Opioid agonist therapy Cannabis 

Notes

Funding Information

MES is supported by Michael Smith Foundation for Health Research (MSFHR) and Canadian Institutes of Health Research (CIHR) fellowship awards. M-JM is supported in part by NIH (U01-DA021525), a Scholar Award from MSFHR and a New Investigator award from the Canadian Institutes of Health Research (CIHR).

Compliance with Ethical Standards

Conflict of Interest

M. Eugenia Socías and MJ Milloy declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Disclosures

M-JM’s institution has received an unstructured gift to support him from NG Biomed Ltd., a private firm seeking a government license to produce medical cannabis.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.  https://doi.org/10.1056/NEJMoa1105243.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281–90.  https://doi.org/10.1016/S1473-3099(13)70692-3.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Insight Start Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.  https://doi.org/10.1056/NEJMoa1506816. CrossRefGoogle Scholar
  4. 4.
    Temprano Anrs Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.  https://doi.org/10.1056/NEJMoa1507198. CrossRefGoogle Scholar
  5. 5.
    •• Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–81.  https://doi.org/10.1001/jama.2016.5148. This study provides among the first estimates of HIV transmission in condomless sex in the context of suppressive ART. CrossRefPubMedGoogle Scholar
  6. 6.
    Mayer KH. Introduction: linkage, engagement, and retention in HIV care: essential for optimal individual- and community-level outcomes in the era of highly active antiretroviral therapy. Clin Infect Dis. 2011;52(Suppl 2):S205–7.  https://doi.org/10.1093/cid/ciq043.CrossRefPubMedGoogle Scholar
  7. 7.
    Mugavero MJ, Norton WE, Saag MS. Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis. 2011;52(Suppl 2):S238–46.  https://doi.org/10.1093/cid/ciq048. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine (Baltimore). 2016;95(15):e3361.  https://doi.org/10.1097/MD.0000000000003361.CrossRefGoogle Scholar
  9. 9.
    Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296(6):679–90.  https://doi.org/10.1001/jama.296.6.679.CrossRefPubMedGoogle Scholar
  10. 10.
    Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.  https://doi.org/10.1371/journal.pmed.0030438.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Langebeek N, Gisolf EH, Reiss P, Vervoort SC, Hafsteinsdottir TB, Richter C, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 2014;12:142.  https://doi.org/10.1186/PREACCEPT-1453408941291432.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14(4):731–47.  https://doi.org/10.1007/s10461-008-9489-7.CrossRefPubMedGoogle Scholar
  13. 13.
    •• Mannheimer S, Hirsch-Moverman Y. What we know and what we do not know about factors associated with and interventions to promote antiretroviral adherence. Curr Infect Dis Rep. 2015;17(4):466.  https://doi.org/10.1007/s11908-015-0466-9. A systematic review of interventions to improve antiretroviral adherence. CrossRefPubMedGoogle Scholar
  14. 14.
    Gonzalez A, Barinas J, O'Cleirigh C. Substance use: impact on adherence and HIV medical treatment. Curr HIV/AIDS Rep. 2011;8(4):223–34.  https://doi.org/10.1007/s11904-011-0093-5.CrossRefPubMedGoogle Scholar
  15. 15.
    Des Jarlais DC, Kerr T, Carrieri P, Feelemyer J, Arasteh K. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. AIDS. 2016;30(6):815–26.  https://doi.org/10.1097/QAD.0000000000001039.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Beer L, Skarbinski J. Adherence to antiretroviral therapy among HIV-infected adults in the United States. AIDS Educ Prev. 2014;26(6):521–37.  https://doi.org/10.1521/aeap.2014.26.6.521.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    De Boni RB, Shepherd BE, Grinsztejn B, Cesar C, Cortes C, Padgett D, et al. Substance use and adherence among people living with HIV/AIDS receiving cART in Latin America. AIDS Behav. 2016;20(11):2692–9.  https://doi.org/10.1007/s10461-016-1398-6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    • Feelemyer J, Des Jarlais D, Arasteh K, Uuskula A. Adherence to antiretroviral medications among persons who inject drugs in transitional, low and middle income countries: an international systematic review. AIDS Behav. 2015;19(4):575–83.  https://doi.org/10.1007/s10461-014-0928-3. A systematic review of ART adherence among people who inject drugs in transitional-, low- and middle-income countries. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Milloy MJ, Wood E, Kerr T, Hogg B, Guillemi S, Harrigan PR, et al. Increased prevalence of controlled viremia and decreased rates of HIV drug resistance among HIV-positive people who use illicit drugs during a community-wide treatment-as-prevention initiative. Clin Infect Dis. 2016;62(5):640–7.  https://doi.org/10.1093/cid/civ929.CrossRefPubMedGoogle Scholar
  20. 20.
    Joseph B, Kerr T, Puskas CM, Montaner J, Wood E, Milloy MJ. Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting. AIDS Care. 2015;27(9):1128–36.  https://doi.org/10.1080/09540121.2015.1032205.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol use and human immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions. Alcohol Clin Exp Res. 2016;40(10):2056–72.  https://doi.org/10.1111/acer.13204.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    •• Vagenas P, Azar MM, Copenhaver MM, Springer SA, Molina PE, Altice FL. The impact of alcohol use and related disorders on the HIV continuum of care: a systematic review : alcohol and the HIV continuum of care. Curr HIV/AIDS Rep. 2015;12(4):421–36.  https://doi.org/10.1007/s11904-015-0285-5. A systematic review of the impact of alcohol use and related disorders on engagement in the HIV continuum of care. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Gonzalez-Alvarez S, Madoz-Gurpide A, Parro-Torres C, Hernandez-Huerta D, Ochoa Mangado E. Relationship between alcohol consumption, whether linked to other substance use or not, and antiretroviral treatment adherence in HIV+ patients. Adicciones. 2017;0(0):916.  https://doi.org/10.20882/adicciones.916.PubMedGoogle Scholar
  24. 24.
    Nolan S, Walley AY, Heeren TC, Patts GJ, Ventura AS, Sullivan MM, et al. HIV-infected individuals who use alcohol and other drugs, and virologic suppression. AIDS Care. 2017;29(9):1129–36.  https://doi.org/10.1080/09540121.2017.1327646.CrossRefPubMedGoogle Scholar
  25. 25.
    Shuper PA, Joharchi N, Irving H, Fletcher D, Kovacs C, Loutfy M, et al. Differential predictors of ART adherence among HIV-monoinfected versus HIV/HCV-coinfected individuals. AIDS Care. 2016;28(8):954–62.  https://doi.org/10.1080/09540121.2016.1158396.CrossRefPubMedGoogle Scholar
  26. 26.
    Azar P, Wood E, Nguyen P, Luma M, Montaner J, Kerr T, et al. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. BMC Infect Dis. 2015;15:193.  https://doi.org/10.1186/s12879-015-0913-0.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    •• Rosen MI, Black AC, Arnsten JH, Goggin K, Remien RH, Simoni JM, et al. Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. AIDS Behav. 2013;17(1):142–7.  https://doi.org/10.1007/s10461-011-0124-7. This study using a large dataset of studies conducted in the USA indicated an association between use of most substances and suboptimal adherence, with the exception of cannabis. CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Gonzalez A, Mimiaga MJ, Israel J, Andres Bedoya C, Safren SA. Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment. AIDS Behav. 2013;17(1):168–73.  https://doi.org/10.1007/s10461-012-0319-6.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hayashi K, Wood E, Kerr T, Dong H, Nguyen P, Puskas CM, et al. Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study. BMC Infect Dis. 2016;16(1):455.  https://doi.org/10.1186/s12879-016-1749-y.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Slawson G, Milloy MJ, Balneaves L, Simo A, Guillemi S, Hogg R, et al. High-intensity cannabis use and adherence to antiretroviral therapy among people who use illicit drugs in a Canadian setting. AIDS Behav. 2015;19(1):120–7.  https://doi.org/10.1007/s10461-014-0847-3.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Vidot DC, Lerner B, Gonzalez R. Cannabis use, medication management and adherence among persons living with HIV. AIDS Behav. 2017;21(7):2005–13.  https://doi.org/10.1007/s10461-017-1782-x.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Bonn-Miller MO, Oser ML, Bucossi MM, Trafton JA. Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. J Behav Med. 2014;37(1):1–10.  https://doi.org/10.1007/s10865-012-9458-5.CrossRefPubMedGoogle Scholar
  33. 33.
    de Jong BC, Prentiss D, McFarland W, Machekano R, Israelski DM. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr. 2005;38(1):43–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Socias ME, Kerr T, Wood E, Dong H, Lake S, Hayashi K, et al. Intentional cannabis use to reduce crack cocaine use in a Canadian setting: a longitudinal analysis. Addict Behav. 2017;72:138–43.  https://doi.org/10.1016/j.addbeh.2017.04.006.CrossRefPubMedGoogle Scholar
  35. 35.
    Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30–5.  https://doi.org/10.1016/j.drugpo.2017.01.011.CrossRefPubMedGoogle Scholar
  36. 36.
    Rajasingham R, Mimiaga MJ, White JM, Pinkston MM, Baden RP, Mitty JA. A systematic review of behavioral and treatment outcome studies among HIV-infected men who have sex with men who abuse crystal methamphetamine. AIDS Patient Care STDs. 2012;26(1):36–52.  https://doi.org/10.1089/apc.2011.0153.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Moore DJ, Blackstone K, Woods SP, Ellis RJ, Atkinson JH, Heaton RK, et al. Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care. 2012;24(12):1504–13.  https://doi.org/10.1080/09540121.2012.672718.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Parsons JT, Kowalczyk WJ, Botsko M, Tomassilli J, Golub SA. Aggregate versus day level association between methamphetamine use and HIV medication non-adherence among gay and bisexual men. AIDS Behav. 2013;17(4):1478–87.  https://doi.org/10.1007/s10461-013-0463-7.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Jeevanjee S, Penko J, Guzman D, Miaskowski C, Bangsberg DR, Kushel MB. Opioid analgesic misuse is associated with incomplete antiretroviral adherence in a cohort of HIV-infected indigent adults in San Francisco. AIDS Behav. 2014;18(7):1352–8.  https://doi.org/10.1007/s10461-013-0619-5.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    •• Low AJ, Mburu G, Welton NJ, May MT, Davies CF, French C, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis. 2016;63(8):1094–104.  https://doi.org/10.1093/cid/ciw416. This systematic review and meta-analysis demonstrated the positive impacts of opioid agonist therapy to improve engagement in each step of the HIV continuum of care. CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Nosyk B, Min JE, Colley G, Lima VD, Yip B, Milloy MJ, et al. The causal effect of opioid substitution treatment on HAART medication refill adherence. AIDS. 2015;29(8):965–73.  https://doi.org/10.1097/QAD.0000000000000642.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lappalainen L, Nolan S, Dobrer S, Puscas C, Montaner J, Ahamad K, et al. Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids. Addiction. 2015;110(8):1330–9.  https://doi.org/10.1111/add.12970.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Rosen MI, Black AC, Arnsten JH, Simoni JM, Wagner GJ, Goggin K, et al. ART adherence changes among patients in community substance use treatment: a preliminary analysis from MACH14. AIDS Res Ther. 2012;9(1):30.  https://doi.org/10.1186/1742-6405-9-30.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Richardson LA, Kerr TH, Dobrer S, Puskas CM, Guillemi SA, Montaner JS, et al. Socioeconomic marginalization and plasma HIV-1 RNA nondetectability among individuals who use illicit drugs in a Canadian setting. AIDS. 2015;29(18):2487–95.  https://doi.org/10.1097/QAD.0000000000000853.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Kennedy MC, Kerr T, McNeil R, Parashar S, Montaner J, Wood E, et al. Residential eviction and risk of detectable plasma HIV-1 RNA viral load among HIV-positive people who use drugs. AIDS Behav. 2017;21(3):678–87.  https://doi.org/10.1007/s10461-016-1315-z.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Milloy MJ, Montaner JS, Wood E. Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV/AIDS Rep. 2014;11(3):308–16.  https://doi.org/10.1007/s11904-014-0214-z.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Milloy MJ, Kerr T, Bangsberg DR, Buxton J, Parashar S, Guillemi S, et al. Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDs. 2012;26(1):60–7.  https://doi.org/10.1089/apc.2011.0169.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Binford MC, Kahana SY, Altice FL. A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV/AIDS Rep. 2012;9(4):287–312.  https://doi.org/10.1007/s11904-012-0134-8.CrossRefPubMedGoogle Scholar
  49. 49.
    Lucas GM, Mullen BA, Galai N, Moore RD, Cook K, McCaul ME, et al. Directly administered antiretroviral therapy for HIV-infected individuals in opioid treatment programs: results from a randomized clinical trial. PLoS One. 2013;8(7):e68286.  https://doi.org/10.1371/journal.pone.0068286.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Farber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, et al. A study of financial incentives to reduce plasma HIV RNA among patients in care. AIDS Behav. 2013;17(7):2293–300.  https://doi.org/10.1007/s10461-013-0416-1.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Solomon SS, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS, Balakrishnan P, et al. Voucher incentives improve linkage to and retention in care among HIV-infected drug users in Chennai, India. Clin Infect Dis. 2014;59(4):589–95.  https://doi.org/10.1093/cid/ciu324.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    • Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016;316(2):156–70.  https://doi.org/10.1001/jama.2016.8914. This randomized clinical trial among hospitalized patients with HIV and substance use found no beneficial effect of patient navigation with or without financial incentives to improve HIV treatment adherence and viral suppression. CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Moore DJ, Montoya JL, Blackstone K, Rooney A, Gouaux B, Georges S, et al. Preliminary evidence for feasibility, use, and acceptability of individualized texting for adherence building for antiretroviral adherence and substance use assessment among HIV-infected methamphetamine users. AIDS Res Treat. 2013;2013:585143.  https://doi.org/10.1155/2013/585143. PubMedPubMedCentralGoogle Scholar
  54. 54.
    Ingersoll K, Dillingham R, Reynolds G, Hettema J, Freeman J, Hosseinbor S, et al. Development of a personalized bidirectional text messaging tool for HIV adherence assessment and intervention among substance abusers. J Subst Abus Treat. 2014;46(1):66–73.  https://doi.org/10.1016/j.jsat.2013.08.002.CrossRefGoogle Scholar
  55. 55.
    • Viswanathan S, Detels R, Mehta SH, Macatangay BJ, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 2015;19(4):601–11.  https://doi.org/10.1007/s10461-014-0927-4 This study estimated the minimum adherence needed to achieve viral suppression with newer antiretroviral regimens in large cohorts of men who have sex with men and people who inject drugs.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Viswanathan S, Justice AC, Alexander GC, Brown TT, Gandhi NR, McNicholl IR, et al. Adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;69(4):493–8.  https://doi.org/10.1097/QAI.0000000000000643. CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Castillo-Mancilla JR, Brown TT, Erlandson KM, Palella FJ Jr, Gardner EM, Macatangay BJ, et al. Suboptimal adherence to combination antiretroviral therapy is associated with higher levels of inflammation despite HIV suppression. Clin Infect Dis. 2016;63(12):1661–7.  https://doi.org/10.1093/cid/ciw650.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.British Columbia Centre on Substance UseVancouverCanada
  2. 2.Department of MedicineUniversity of British ColumbiaVancouverCanada

Personalised recommendations